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Respiratory syncytial virus (RSV) is the most significant
cause of acute respiratory tract infections in infants and
young children worldwide. RSV accounts for approxi-
mately 70% of hospitalizations for bronchiolitis and 40%
of pneumonia among infants <1 year of life.
RSV infection seems to be associated with recurrent
wheezing during the first decade of life and impaired
respiratory health-related quality of life in adults [1].
Universal prevention of RSV infection is based on
environmental prophylaxis aimed at minimizing the
spread of the virus good hand hygiene in the home, and
limiting direct contact of high-risk children with other
children and adults with respiratory tract infections.
Exposure to tobacco smoke should be avoid in family
with infants, breastfeeding should be encouraged.Phar-
macological prophylaxis is based on the administration
of palivizumab (Synagis®, MedImmune) during the epi-
demic period to the children at risk [2].
Palivizumab is a humanized monoclonal antibody
directed to an epitope in the A antigenic site of F pro-
tein of RSV. It is designed to provide passive immunity
against RSV and thereby prevent or reduce the severity
of RSV infection [2].
The aim of this work is to provide Italian neonatolo-
gists shared recommendations regarding palivizumab
use in premature and other at-risk infants in the light of
new emerging evidence.
The peak incidence of severe RSV disease occurs
between 2 and 3 months of age. The risk of serious RSV
illness is highest among preterm neonates, children with
chronic lung disease, congenital heart disease [3,4].
The children with the above mentioned clinical condi-
tions, particularly in cases of hospitalization, are more
likely to require admission to an intensive care unit and
need mechanical ventilation. In addition they have high
rates of re-hospitalization for lower respiratory tract
infections [5,6].
Therefore, all these categories of infants are likely to
benefit from prophylaxis, and have been included in the
recommendations. Specific recommendations are pro-
vided according to gestational age at birth
RSV infections occur most frequently during the per-
iod between October-March.
According to this observation, prophylaxis with Palivi-
zumab is indicated in this 5-6 months long seasonal
window of RSV infection.
The duration of prophylaxis (up to one year or up to
two years of life during the seasonal period) depends on
the underlying condition.
Palivizumab is clinically effective; however, the cost is
very high. In our opinion strict criteria for patient selec-
tion and reduced drug costs would improve the cost-
effectiveness of the prophylaxis [7].
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